Saudi-Arabien - Englisch - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

pharma international co., jordan - ciprofloxacin - film-coated tablet - 250 mg

Saudi-Arabien - Englisch - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

med city pharma, saudi arabia - ciprofloxacin - film-coated tablet - 500 mg

Jordanien - Englisch - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

الشركة الدولية للدواء - pharma international company - ciprofloxacin 500 mg - 500 mg

Uganda - Englisch - National Drug Authority

pharma international.co - ciprofloxacin - oral solid ordinary film-coated tablets - 500mg

Europäische Union - Englisch - EMA (European Medicines Agency)

roche registration gmbh - atezolizumab - carcinoma, transitional cell; carcinoma, non-small-cell lung; urologic neoplasms; breast neoplasms; small cell lung carcinoma - antineoplastic agents - urothelial carcinomatecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc):- after prior platinum containing chemotherapy, or - who are considered cisplatin ineligible, and whose tumours have a pd-l1 expression ≥ 5% (see section 5.1).non-small cell lung cancer tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous non small cell lung cancer (nsclc). in patients with egfr mutant or alk-positive nsclc, tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapies (see section 5.1).tecentriq, in combination with nab paclitaxel and carboplatin, is indicated for the first line treatment of adult patients with metastatic non-squamous nsclc who do not have egfr mutant or alk positive nsclc (see section 5.1).tecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumours have a pd-l1 expression ≥ 50% tumour cells (tc) or ≥ 10% tumour-infiltrating immune cells (ic) and who do not have egfr mutant or alk-positive nsclc (see section 5.1).tecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic nsclc after prior chemotherapy. patients with egfr mutant or alk positive nsclc should also have received targeted therapies before receiving tecentriq (see section 5.1).small cell lung cancertecentriq, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (es-sclc) (see section 5.1).hepatocellular carcinomatecentriq, in combination with bevacizumab, is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (hcc) who have not received prior systemic therapy (see section 5.1).urothelial carcinomatecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc):- after prior platinum containing chemotherapy, or- who are considered cisplatin ineligible, and whose tumours have a pd-l1 expression ≥ 5% (see section 5.1).non-small cell lung cancertecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumours have a pd-l1 expression ≥ 50% tumour cells (tc) or ≥ 10% tumour-infiltrating immune cells (ic) and who do not have egfr mutant or alk-positive nsclc (see section 5.1).tecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic nsclc after prior chemotherapy. patients with egfr mutant or alk positive nsclc should also have received targeted therapies before receiving tecentriq (see section 5.1).triple-negative breast cancertecentriq in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (tnbc) whose tumours have pd-l1 expression ≥ 1% and who have not received prior chemotherapy for metastatic disease.

Israel - Englisch - Ministry of Health

propharm ltd - bethanechol chloride - tablets - bethanechol chloride 25 mg - bethanechol - myocholine glenwood is indicated in cases of postoperative urinary retention due to atony of the bladder in adults in diseases in which a stimulation of the bladder muscle is needed.

Israel - Englisch - Ministry of Health

propharm ltd - caspofungin as acetate - powder for concentrate for solution for infusion - caspofungin as acetate 50 mg - caspofungin - caspofungin wockhrdt is indicated in adults and pediatric patients (3 months and older) for:- empirical therapy for presumed fungal infections in febrile, neutropenic patients.- treatment of candidemia and the following candida infections: intra-abdominal abscesses, peritonitis and pleural space infections. caspofungin has not been studied in endocarditis, ostemyelitis, and meningitis due to candida.- treatment of esophageal candidiasis.- treatment of invasive aspergillosis in patients who are refractory to or intolerant to other therapies (i.e. amphotericin b, lipid formulations of amphotericin b, and/or itraconazole). caspofungin has not been studied as initial therapy for invasive aspergillosis

Israel - Englisch - Ministry of Health

propharm ltd - caspofungin as acetate - powder for concentrate for solution for infusion - caspofungin as acetate 70 mg - caspofungin - caspofungin wockhrdt is indicated in adults and pediatric patients (3 months and older) for:- empirical therapy for presumed fungal infections in febrile, neutropenic patients.- treatment of candidemia and the following candida infections: intra-abdominal abscesses, peritonitis and pleural space infections. caspofungin has not been studied in endocarditis, ostemyelitis, and meningitis due to candida.- treatment of esophageal candidiasis.- treatment of invasive aspergillosis in patients who are refractory to or intolerant to other therapies (i.e. amphotericin b, lipid formulations of amphotericin b, and/or itraconazole). caspofungin has not been studied as initial therapy for invasive aspergillosis

Europäische Union - Englisch - EMA (European Medicines Agency)

elanco gmbh - tulathromycin - antibacterials for systemic use - cattle; pigs; sheep - cattle: treatment and metaphylaxis of bovine respiratory disease (brd) associated with mannheimia haemolytica, pasteurella multocida, histophilus somni and mycoplasma bovis susceptible to tulathromycin. the presence of the disease in the herd should be established before metaphylactic treatment.treatment of infectious bovine keratoconjunctivitis (ibk) associated with moraxella bovis susceptible to tulathromycin.pigs: treatment and metaphylaxis of swine respiratory disease (srd) associated with actinobacillus pleuropneumoniae, pasteurella multocida, mycoplasma hyopneumoniae, haemophilus parasuis and bordetella bronchiseptica susceptible to tulathromycin. the presence of the disease in the herd should be established before metaphylactic treatment. the product should only be used if pigs are expected to develop the disease within 2–3 days.sheep: treatment of the early stages of infectious pododermatitis (foot rot) associated with virulent dichelobacter nodosus requiring systemic treatment.

Malta - Englisch - Medicines Authority

1 a pharma gmbh keltenring 1+3, 82041 oberhaching, germany - gemcitabine - powder for solution for infusion - gemcitabine 1000 mg - antineoplastic agents